{
    "identificationModule": {
        "nctId": "NCT01328951",
        "orgStudyIdInfo": {
            "id": "BO25460"
        },
        "organization": {
            "fullName": "Hoffmann-La Roche",
            "class": "INDUSTRY"
        },
        "briefTitle": "A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy",
        "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Phase III Study of First-Line Maintenance Tarceva Versus Tarceva at the Time of Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following 4 Cycles of Platinum-Based Chemotherapy"
    },
    "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults greater than or equal to (\u2265) 18 years of age, or legal age of consent if greater than 18\n* Advanced or recurrent (Stage IIIB) or metastatic (Stage IV) NSCLC\n* Completion of 4 cycles of platinum-based chemotherapy without progression (end of last chemotherapy cycle less than or equal to \\[\u2264\\] 28 days prior to randomization)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\nExclusion Criteria:\n\n* Prior exposure to agents directed at human epidermal growth factor receptor (HER) axis (e.g. erlotinib, gefitinib, cetuximab)\n* Participants whose tumors harbor an EGFR-activating mutation\n* Prior chemotherapy or therapy with systemic anti-neoplastic therapy for advanced disease before Screening\n* Use of pemetrexed in maintenance setting (pemetrexed allowed during the chemotherapy run-in)\n* Participants who have undergone complete tumor resection after responding to the platinum-based chemotherapy during the Screening phase\n* Any other malignancies within 5 years, except for curatively resected carcinoma in situ of the cervix, basal or squamous cell skin cancer, ductal carcinoma in situ, or organ-confined prostate cancer\n* Central nervous system (CNS) metastases or spinal cord compression that has not been definitely treated with surgery and/or radiation, or treated CNS metastases or spinal cord compression without stable disease for \u22652 months\n* Human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection\n* Any inflammatory changes of the surface of the eye",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": [
            "ADULT",
            "OLDER_ADULT"
        ]
    }
}